Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
ESMO 2025 preview – Astra joins the folate fray
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
